AbbVie’s Biologic License Application for Skyrizi approved by FDA, according to a statement posted on the agency’s website.
- Canada and Japan had already approved Skyrizi (risankizumab) for treatment of plaque psoriasis, AbbVie said last week
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.